CMPS
COMPASS Pathways plc
Set alert
11.57 USD -0.62 -5.09%
11.27 Day range 11.99
4.94 52-week range 15.19
- YTD
- +67.68%
- 1 year
- +83.65%
- Open
- 11.82
- Prev close
- 12.19
- Mkt cap
- 1.60B
- Vol
- 2.18M
- Avg vol
- 2.65M
- EPS
- -3.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.27
- High
- 11.99
- Forward P/E
- -8.07
- Beta
- 2.56
- Short ratio
- 6.40
- Inst. own
- 69.35%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 12.95
- 200-d avg
- 10.38
- 1y target
- 23.75
Key statistics
- Market cap
- 1.60B
- Enterprise value
- 1.31B
- Trailing P/E
- 0.00
- Forward P/E
- -8.07
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 18.57
- EPS (TTM)
- -3.76
- Beta
- 2.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 249.95M
- Total cash
- 433.30M
- Total debt
- 54.63M
- Return on equity
- -319.07%
- Shares outstanding
- 138.48M
- Short % of float
- 12.93%
- 50-day average
- 12.95
- 200-day average
- 10.38
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 23.75 +105.3% upside
Now 11.57
- Target (low)
- 13.00
- Target (mean)
- 23.75
- Target (high)
- 65.00
Ratings (0m) 16 15 buy · 1 hold · 0 sell
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.33.
Financials — quick view
CMPS Revenue — quarterly 0
CMPS Net income — quarterly -253.79M
CMPS EPS — quarterly -1.88
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.39 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -0.46 | -0.36 | +0.10 | +21.74% |
| May 13, 2026 | Mar 31, 2026 | -0.45 | -0.30 | +0.15 | +33.33% |
| Mar 24, 2026 | Dec 31, 2025 | -0.41 | -1.00 | -0.59 | -143.90% |
| Nov 4, 2025 | Sep 30, 2025 | -0.40 | -1.44 | -1.04 | -260.00% |
| Jul 31, 2025 | Jun 30, 2025 | -0.37 | -0.38 | -0.01 | -2.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 6, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 6, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 6, 2026 | B. Riley Securities | main | Buy | Buy |
| Jul 27, 2026 | Wells Fargo | init | — | Equal-Weight |
| Jul 8, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About COMPASS Pathways plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- United Kingdom
- Website
- compasspathways.com
News
- Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
- Compass Pathways: A Compelling Opportunity In A Large And Underserved Market
- Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
- Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales
- Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
- Compass Pathways Reports Q2 2026 Results: Full Earnings Call Transcript
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Target Price of $23.36 According to Brokerages
- Compass Pathways Appoints Kelley Boucher as Chief People Officer
- Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch
Your note
Sign in to keep a note on CMPS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LOXAM TERI | Chief Financial Officer | Stock Award(Grant) | Mar 25, 2026 | 152,002 |
| NATH KABIR | Chief Executive Officer | Stock Award(Grant) | Mar 25, 2026 | 366,990 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 8.78% | 12,161,496 | 140.71M | Jun 29, 2026 |
| RTW Investments LP | 7.73% | 10,700,974 | 123.81M | Jun 29, 2026 |
| BIT Capital GmbH | 4.58% | 6,348,797 | 73.46M | Jun 29, 2026 |
| Tang Capital Management, LLC | 3.61% | 5,000,000 | 57.85M | Jun 29, 2026 |
| Two Sigma Investments, LP | 3.23% | 4,470,485 | 51.72M | Jun 29, 2026 |
| Marshall Wace LLP | 3.13% | 4,328,682 | 50.08M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Genomic Revolution ETF | 3.32% | 4,591,088 | 53.12M | Sep 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.64% | 886,679 | 10.26M | Sep 29, 2026 |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.35% | 482,715 | 5.59M | Sep 29, 2026 |
| ROYCE FUND-Royce Smaller-Companies Growth Fund | 0.13% | 178,000 | 2.06M | Jun 29, 2026 |
| ALPS ETF TRUST-ALPS Medical Breakthroughs ETF | 0.12% | 166,501 | 1.93M | Aug 30, 2026 |
| Goldman Sachs Trust-Goldman Sachs Small Cap Growth Fund | 0.11% | 152,301 | 1.76M | Aug 30, 2026 |